ea0035s22.2 | Novel therapies for thyroid cancer | ECE2014
Leboulleux Sophie
Targeted therapies have been used for about 10 years in patients with radioactive iodine refractory differentiated thyroid cancer (DTC) or metastatic medullary thyroid cancer (MTC). Decrease in tumor volume, improvement of symptoms, increase in progression free survivals have been observed with different drugs. So far, because of trial design and because of the long survival of patients with metastatic DTC or MTC, the benefit of these drugs on overall survival has not been dem...